

Cover Story
NCINews Analysis
Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets



CURRENT ISSUE



CURRENT ISSUE
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Jonathan Licht named president, chief scientific officer at Van Andel Institute












